Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05319028 · ClinicalTrials.gov registry record · Phase 2
Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
A Phase 2 study, sponsored by Calithera Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT05319028 is a Phase 2 study that was terminated before completion, run by Calithera Biosciences. The registered enrollment target is 2 participants.
The verdict
NCT05319028, a Phase 2 study, was terminated before completion, sponsored by Calithera Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Study CX-659-401 is a multicenter, open-label, phase 2 study of mivavotinib to evaluate the single-agent activity of mivavotinib in patients with relapsed/refractory non-GCB/ABC DLBCL, incorporating ctDNA-based next-generation sequencing (NGS) to identify DLBCL patients harboring MyD88 and/or CD79B mutations within the study. This goal of this strategy is to evaluate its activity both in the cell-of-origin subgroup of non-GCB/ABC DLBCL and in the genetically defined subgroups of MyD88/CD79B-mutated and wild type DLBCL.
Interventions
- DRUG Mivavotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-06-23 |
| Est. Completion | 2023-02-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05319028
The ClinicalTrials.gov registry entry for NCT05319028 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calithera Biosciences, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mivavotinib is the first listed.
NCT05319028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05319028 about?
NCT05319028 is a clinical study titled "Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)". Study CX-659-401 is a multicenter, open-label, phase 2 study of mivavotinib to evaluate the single-agent activity of mivavotinib in patients with relapsed/refractory non-GCB/ABC DLBCL, incorporating ctDNA-based next-generation sequencing (NGS) to identify DLBCL patients harboring MyD88 and/or CD79B ...
What is the current status of trial NCT05319028?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2022-06-23. Estimated completion is 2023-02-24.
What interventions are being tested in trial NCT05319028?
The interventions under investigation include: Mivavotinib (DRUG).
Who is sponsoring clinical trial NCT05319028?
This trial is sponsored by Calithera Biosciences, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.